Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Behav Pharmacol. 2012 Jun;23(3):271–279. doi: 10.1097/FBP.0b013e3283536d6f

Figure 4.

Figure 4

Peak participant ratings (mean ± SEM) of the subjective drug value of placebo and oxycodone doses as measured by the VAS during the intermittent (left panels) and daily (right panels) dosing phases during the first and second sessions as a function of cumulative oxycodone dose. See Figure 1 legend for details.